|Endo International plc, of Dublin||Collagenase clostridium histolyticum||Enzyme targeting collagen||Cellulite in the buttocks||FDA accepted the BLA; PDUFA action date of July 6, 2020|
|Hope Biosciences Inc., of Houston||HB-adMSCs||Autologous, adipose-derived mesenchymal stem cells||Alzheimer’s disease||FDA approved the 24-patient phase I/II study|
|Kiniksa Pharmaceuticals Ltd., Hamilton, Bermuda||Rilonacept||Fusion protein that blocks IL-1alpha and IL-1beta signaling||Recurrent pericarditis||FDA granted breakthrough therapy designation|
|Merck & Co. Inc., of Kenilworth, N.J.||Keytruda (pembrolizumab)||Monoclonal antibody targeting PD-1||Metastatic or unresectable recurrent head and neck squamous cell carcinoma expressing PD-L1||European Commission approved the expanded indication as a monotherapy or in combination with platinum and 5-fluorouracil chemotherapy|
|Merck KGaA, of Darmstadt, Germany||Tepotinib||MET inhibitor||Non-small-cell lung cancer with MET gene alterations||Japanese Ministry of Health, Labour and Welfare granted orphan drug designation|
|OWP Pharmaceuticals Inc., Naperville, Ill.||Liquid formulation of topiramate||Targets voltage-dependent sodium channels, GABA receptors and glutamate receptors||Epilepsy and migraine||FDA approved IND|
|Vertical Pharmaceuticals LLC, of Bridgewater, N.J.||RVL-1201||Ophthalmic formulation of alpha-adrenergic receptor agonist oxymetazoline||Acquired blepharoptosis||FDA accepted the NDA; PDUFA action date of July 16, 2020|
For more information about individual companies and/or products, see Cortellis.